About Orca Bio
Orca Bio is a Healthcare company based in Menlo Park (United States) founded in 2016 by Jeroen Bekaert, Ivan Dimov, and Nathaniel fernhoff. Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. Orca Bio has raised $300 million across 2 funding rounds from investors including Kaiser Permanente, Lightspeed Venture Partners and Mubadala. The company has 384 employees. Orca Bio was last valued at $2.4 billion in January 2023. Its chief executive, as recorded, is Ivan Dimov. Orca Bio offers products and services including Orca-T and Orca-Q. Its focus areas include Life Sciences, Immunology, Drugs and Autoimmune Diseases. Its competitors include Moderna, Forge Biologics and Annexon; 3 of its 3 listed competitors have raised funding.
Company details
Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patients new immune system.
- Headquarters Menlo Park, United States
- Employees 384
- Founders Jeroen Bekaert, Ivan Dimov, Nathaniel fernhoff
- Stage Unicorn
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website orcabio.com
- Social LinkedIn X Facebook
- Total Equity Funding$300M (USD)
in 2 rounds
- Latest Funding Round$250M (USD), Series F
Jan 2026
- InvestorsKaiser Permanente
& 12 more
- Employee Count384
Products & Services of Orca Bio
Orca Bio offers a comprehensive portfolio of products and services, including Orca-T and Orca-Q.
Investigational therapy targeting cancer with high-precision T-cells
Investigational therapy for autoimmune diseases using advanced cells
Funding Insights of Orca Bio
Orca Bio has successfully raised a total of $300M across 2 strategic funding rounds. The most recent funding activity was a Series F round of $250 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $300M
- Total Rounds 2
- Last Round Series F — $250M
- First Round $192M
(Nov 2019)
- Investors Count 13
All 2 funding rounds of Orca Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $250M | Series F | – | Lightspeed Venture Partners | – |
| Nov 2019 | $192M | Series D | – | Lightspeed Venture Partners |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Orca Bio
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $2.4B (Jan 2023). 13 investors in total: 13 institutional.
Investors in Orca Bio
Orca Bio has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Kaiser Permanente, Lightspeed Venture Partners and Mubadala.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners. | 1997 | lsvp.com | Menlo Park, United States | |
Venture capital firm investing in technology, life sciences, and related sectors. | 8vc.com | |||
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Tech startups are invested in by this venture capital firm. | nd.capital | Woodside, United States | ||
Dream Variation Ventures is engaged in venture capital investments. | dreamvariation.com | |||
Investments in technology startups are made by Felicis Ventures. | unknown_b397d6e4b8c74d5f8 | Menlo Park, United States | ||
| lh-ventures.com | ||||
Industrial investments are managed by the UK-based firm. | industrial-investors.com | London, United Kingdom | ||
Early-stage venture capital investments are made in innovative founders. | 2018 | valleycapital.vc | ||
Mubadala Capital is engaged in investment management services. | mubadalacapital.ae |
Investor details for Orca Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Orca Bio
88 people are tracked at Orca Bio (29 in leadership, 8 in board & advisors, 51 in team); the tracked headcount is 384.
| Name | Role | Group |
|---|---|---|
Jeroen Bekaert | Co-Founder & COO | Leadership |
Ivan Dimov | Co-Founder & CEO | Leadership |
Nathaniel fernhoff | Founder | Leadership |
Steve Russo | Associate Director, Market Development-east | Leadership |
Katie Chaddock | Site Head Of Commercial Manufacturing | Leadership |
Lisa Chen | Strategic People Partner | Leadership |
Tamas Blandl | Vice President, Manufacturing And CMC Development | Leadership |
James Scott McClellan | Chief Medical Officer | Leadership |
Kate Bickett | Head Of Clinical Operations | Leadership |
Ethan Galloway | Vice President, Head Of Marketing And New Product Planning | Leadership |
Virginia Sullivan | Head Of Product Supply | Leadership |
Anna Pavlova | Senior Medical Director | Leadership |
Adria Carbo | Vice President, Head Of Business Development | Leadership |
Khiem do | Director Of Engineering | Leadership |
Abby G. | Head Of People At Orca Bio (vice President) | Leadership |
Tony Cano | Executive Director, CMC Process Development | Leadership |
Karin McIntosh | Head Of Regulatory Affairs | Leadership |
Michele Salierno | Head Of Strategy And Analytics | Leadership |
Hua Z. | Director, CMC Analytical Development | Leadership |
Deepthi Mikkili | Director, Clinical Data Management | Leadership |
68 more people are available in the full profile.
Complete people profiles for Orca Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Orca Bio
4 dated milestones of Orca Bio across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Orca Bio is founded.
- Funding First funding round of $192.0M.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Series F, of $250.0M.
Competitors of Orca Bio
Orca Bio has 3 listed competitors in our database, 3 of them funded. They include Moderna, Forge Biologics and Annexon.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases |
Detailed competitors of Orca Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Orca Bio
The website of Orca Bio (orcabio.com) receives about 7.8K visits a month and ranks #3,522,870 among all websites worldwide, #4,566 in Biotechnology and Pharmaceuticals.
- Monthly visits7.8K
▲ 40.3% vs previous month
- Unique visitors2.8K
per month
- Global rank#3,522,870
among all websites
- Category rank#4,566
Health · Biotechnology and Pharmaceuticals
- Bounce rate50%
- Pages per visit1.6
- Average visit23 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Orca Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| molecularmatrix.com | 100% | 1.5K | #11,523,751 | View details | |
targetedonc.com | targetedonc.com | 46% | #379,902 | – | |
| gsk.com | 46% | 1.3M | #56,834 | View details | |
| nivagen.com | 23% | 8.5K | #2,347,838 | View details | |
cichlidresearch.com | cichlidresearch.com | 23% | #14,672,194 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Orca Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Orca Bio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orca Bio
Complete news archive for Orca Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orca Bio
Orca Bio was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Orca Bio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Ivan Dimov is the CEO of Orca Bio, as recorded in our data. They have also founded this company.
Orca Bio is a funded company, having raised a total of $300M across 2 funding rounds to date. The company's 1st funding round was a Series D of $192M, raised on Nov 2019.
Orca Bio has 384 employees.
Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patients new immune system.
Orca Bio's top competitors include Moderna, Forge Biologics and Annexon.
Orca Bio offers Orca-T and Orca-Q.
Orca Bio has 13 investors. Key investors include Kaiser Permanente, Lightspeed Venture Partners, Mubadala, 8VC, and DCVC.
The valuation of Orca Bio is $2.4B as of Jan 2023.